Emerging Role of GLP-1 Agonists in Obesity: A Comprehensive Review of Randomised Controlled Trials
Obesity is a chronic disease with high prevalence and associated comorbidities, making it a growing global concern. These comorbidities include type 2 diabetes, hypertension, ventilatory dysfunction, arthrosis, venous and lymphatic circulation diseases, depression, and others, which have a negative...
Main Authors: | Mihaela-Simona Popoviciu, Lorena Păduraru, Galal Yahya, Kamel Metwally, Simona Cavalu |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-06-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/24/13/10449 |
Similar Items
-
Review of upcoming and currently available anti-obesity drugs in Europe
by: Patryk Gryszkiewicz, et al.
Published: (2023-05-01) -
GLP-1 agonists in treatment of obesity
by: Władysław Orłowski, et al.
Published: (2023-01-01) -
Editorial: Incretin agonists in the treatment of obesity
by: Xiaodong Sun, et al.
Published: (2023-08-01) -
Therapeutic Mechanisms and Clinical Effects of Glucagon-like Peptide 1 Receptor Agonists in Nonalcoholic Fatty Liver Disease
by: Han Ah Lee, et al.
Published: (2023-05-01) -
GLP-1 Receptor Agonists in Diabetic Kidney Disease: From Clinical Outcomes to Mechanisms
by: Daiji Kawanami, et al.
Published: (2020-06-01)